ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Últimos 235 días · 12/11/25 — 29/10/26
+38.84%
Precio
$ 48.840
Var. %
+1,96%
Volumen operado
2.059
Precio ABBV
US$ 294,88
Teórico (precio / ratio)
ABBV ÷ 10
US$ 29,49
Yield y fechas del subyacente vía Yahoo Finance. Ver calendario de dividendos.
Yield (USD)
2,4 %
Frecuencia (estimada)
Trim.
Próxima ex-date
sin fecha
Próximo pago
15/11
Cobro estimado (anual)
Dividendo anual USD ÷ ratio 10
USD 0,69
Sí, existe el CEDEAR de ABBV (AbbVie Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es ABBV.
El ticker del CEDEAR de AbbVie Inc. en Argentina es ABBV. La acción subyacente cotiza en NYSE con el símbolo ABBV.
El CEDEAR ABBV tiene un ratio de 10:1. Eso significa que 10 CEDEARs equivalen a 1 acción de ABBV.
El CEDEAR ABBV cotiza hoy a $ 48.840 en pesos argentinos, con una variación diaria de +1,96%.
Otros CEDEARs de Salud.
Yahoo · 30 de oct de 2026
Big Tech is dragging the Nasdaq toward its worst open in weeks while Dow components post earnings beats and barely budge. Whether the damage stays contained or…
Yahoo · 30 de oct de 2026
Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.3% year on year to $17.4 billion. Its non-GA…
Yahoo · 30 de oct de 2026
HDV switched to monthly payments and split its shares this year, and both moves look dramatic on paper until you dig into what actually changed for retirees cou…
Precio de cierre en pesos argentinos. Fuente: data912.
Cotización
US$ 30,94
vs teórico
+4,92%
Cotización MEP implícita
$ 1.578,54
Cotización
US$ 29,97
vs teórico
+1,63%
Cotización Cable implícita
$ 1.629,63
La acción subyacente ABBV (AbbVie Inc.) cotiza a US$ 294,88 en su mercado de origen (NYSE).
El precio teórico del CEDEAR ABBV se calcula dividiendo el precio de ABBV por el ratio (10). Hoy resulta en US$ 29,49.
En BYMA podés operar ABBV en pesos, ABBVD en dólar MEP y ABBVC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR ABBV en pesos argentinos, con datos de data912.
Yahoo · 30 de oct de 2026
AbbVie stock slipped slightly Friday, but the drug giant easily beat third-quarter forecasts with the help of its biggest drug, Skyrizi.
Yahoo · 30 de oct de 2026
Investing.com -- AbbVie Inc. (NYSE:ABBV) reported third-quarter results that exceeded analyst expectations, though shares are down 3% premarket as the company's…
ChartMill · 30 de oct de 2026
AbbVie’s Q3 2026 results were in line with estimates; raised guidance and dividend signal confidence despite a slightly lower pre-market reaction.
Yahoo · 30 de oct de 2026
Key TakeawaysAbbVie stock is up in the past month to a new 52-week high, mostly because investors moved out of AI stocks and into big drugmakers led by Eli Lill…
Yahoo · 30 de oct de 2026
AbbVie (ABBV) delivered earnings and revenue surprises of +2.14% and +0.20%, respectively, for the quarter ended September 2026. Do the numbers hold clues to wh…
Noticias vía Finnhub